143 related articles for article (PubMed ID: 37706580)
1. Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial.
Wang H; Wang N; Wang L; Du J; Li F; Shao Y; Peng B; Luan S; Wang L; Jin X; Gao C; Dou L; Liu D
Am J Hematol; 2023 Nov; 98(11):1732-1741. PubMed ID: 37706580
[TBL] [Abstract][Full Text] [Related]
2. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
3. High Risk of Recurrence of Malignancy Noted in Four-day rATG Regimen After Allogeneic PBSCT From Matched Sibling Donors.
Wang N; Wang H; Fang S; Du J; Huang S; Li F; Jin X; Jia M; Xu L; Dou L; Liu D
Transplant Cell Ther; 2022 Nov; 28(11):769.e1-769.e9. PubMed ID: 35973670
[TBL] [Abstract][Full Text] [Related]
4. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study.
Li X; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Tong Y; Dong B; Wan L; Song X
Front Immunol; 2023; 14():1252879. PubMed ID: 37954615
[TBL] [Abstract][Full Text] [Related]
5. Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis.
Zhou X; Cai Y; Yang J; Tong Y; Qiu H; Huang C; Zhou K; Xu X; Niu J; Xia X; Zhang Y; Shen C; Wei Y; Song X; Wan L
Cell Transplant; 2022; 31():9636897221079739. PubMed ID: 35225024
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Cord Blood Transplantation with 8 mg/kg Antithymocyte Globulin as Graft-versus-Host Disease Prophylaxis Compared to Haploidentical Transplantation with 10 mg/kg Antithymocyte Globulin in the Treatment of Acute Leukemia.
Yuan F; Li G; Li M; Wei X; Fu Y
Transplant Cell Ther; 2023 Dec; 29(12):771.e1-771.e10. PubMed ID: 37748539
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
8. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
[TBL] [Abstract][Full Text] [Related]
9. Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia.
Barkhordar M; Kasaeian A; Janbabai G; Kamranzadeh Fumani H; Tavakoli S; Rashidi AA; Mousavi SA; Ghavamzadeh A; Vaezi M
Front Immunol; 2022; 13():921293. PubMed ID: 35990618
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
Zhou L; Gao ZY; Lu DP
Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
[TBL] [Abstract][Full Text] [Related]
11. Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft
Li T; He Q; Yang J; Cai Y; Huang C; Xu X; Qiu H; Niu J; Zhou K; Zhang Y; Xia X; Wei Y; Shen C; Ding X; Tong Y; Wan L; Song X
Cell Transplant; 2022; 31():9636897221139103. PubMed ID: 36433646
[TBL] [Abstract][Full Text] [Related]
12. Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies.
Chen TT; Lin CC; Lo WJ; Hsieh CY; Lien MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
Int J Hematol; 2022 Apr; 115(4):525-533. PubMed ID: 35226308
[TBL] [Abstract][Full Text] [Related]
13. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.
Lin R; Wang Y; Huang F; Fan Z; Zhang S; Yang T; Xu Y; Xu N; Xuan L; Ye J; Sun J; Huang X; Liu Q
BMC Med; 2019 Aug; 17(1):156. PubMed ID: 31401973
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
15. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial.
Admiraal R; Nierkens S; Bierings MB; Bredius RGM; van Vliet I; Jiang Y; Lopez-Yurda M; Versluijs AB; Zwaan CM; Lindemans CA; Boelens JJ
Lancet Haematol; 2022 Feb; 9(2):e111-e120. PubMed ID: 35114150
[TBL] [Abstract][Full Text] [Related]
16. Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation.
Gao F; Shi Z; Shi J; Luo Y; Yu J; Fu H; Lai X; Liu L; Yuan Z; Zheng Z; Huang H; Zhao Y
HLA; 2024 Jan; 103(1):e15320. PubMed ID: 38081622
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation.
Mountjoy L; Jain T; Kunze KL; Khera N; Sproat LZ; Jennifer W; McCallen M; Leis JF; Noel P; Slack JL; Palmer J
Leuk Lymphoma; 2020 Aug; 61(8):1996-2002. PubMed ID: 32281491
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low dose antithymocyte globulin on overall survival, relapse rate, and infectious complications following allogeneic peripheral blood stem cell transplantation for leukemia in children.
Kang HM; Kim SK; Lee JW; Chung NG; Cho B
Bone Marrow Transplant; 2021 Apr; 56(4):890-899. PubMed ID: 33199818
[TBL] [Abstract][Full Text] [Related]
19. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
